Samer Homsi, MD
Pulmonary Disease · Little Rock, ARNPI 1366604902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 548 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,397, more than ten times the $56 reported in 2019.
Across 548 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Mallinckrodt Hospital Products Inc.$538
- Electromed, Inc.$521
- Sanofi$432
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,16197%
- Education$2493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 178 | $2,196 |
| AstraZeneca | 108 | $1,789 |
| Boehringer Ingelheim | 62 | $1,026 |
| Mallinckrodt Hospital Products Inc. | 23 | $538 |
| Electromed, Inc. | 17 | $521 |
| Sanofi | 21 | $432 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $294 |
| Harmony Biosciences LLC | 11 | $280 |
| Regeneron Healthcare Solutions, Inc. | 13 | $252 |
| Mylan Specialty L.p. | 11 | $239 |
| United Therapeutics Corporation | 9 | $212 |
| Insmed, Inc. | 8 | $195 |
| Baxter Healthcare | 9 | $194 |
| Merck | 7 | $143 |
| Viatris Specialty LLC | 5 | $123 |
| Philips North America LLC | 7 | $121 |
| ANI Pharmaceuticals, Inc. | 5 | $100 |
| Genentech USA, Inc. | 6 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Amgen | 4 | $78 |
| Verona Pharma, Inc. | 3 | $72 |
| Inspire Medical Systems, Inc. | 1 | $52 |
| CSL Behring | 2 | $52 |
| Grifols USA, LLC | 3 | $50 |
| Vifor Pharma, Inc. | 3 | $50 |
| Intuitive Surgical | 1 | $46 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Bayer | 2 | $30 |
| Advanced Respiratory, Inc | 2 | $29 |
| Inogen, Inc. | 2 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| 3b Medical, Inc. | 1 | $17 |
| ERBE USA Inc | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$9,410 in reported general payments places this provider in the 75th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $261,083 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $143,212 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $92,959 |
| Breo ElliptaFluticasone/Vilanterol | 123 | $54,405 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $32,832 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $19,095 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,517 |
| EliquisApixaban | 27 | $12,777 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $12,099 |
| Sildenafil Citrate | 20 | $11,193 |
| Arnuity ElliptaFluticasone Furoate | 32 | $9,005 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,714 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $6,707 |
| Atrovent HfaIpratropium Bromide | 13 | $5,790 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,026 | $292,22374 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,196 | $208,296394 claims |
| Grifols USA, LLCProlastin C | $50 | $143,21212 claims |
| AstraZenecaSymbicort | $1,789 | $8,71432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
- Nancy RectorLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.